BDRX 주가 차트
BDRX 수입
Biodexa Pharmaceuticals PLC
$3.51
-5.27%
$-0.19
오늘 기준:May 14, 12:31:07 GMT-4
뒤로
Biodexa Pharmaceuticals PLC (BDRX) 수입
Earnings FAQ
BDRX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Biodexa Pharmaceuticals PLC BDRX의 지난 분기 매출 실적은 어땠나요?
Biodexa Pharmaceuticals PLC의 매출 추정치는 얼마인가요?
Biodexa Pharmaceuticals PLC의 수익 품질 점수는 얼마인가요?
Biodexa Pharmaceuticals PLC는 언제 수익을 보고하나요?
Biodexa Pharmaceuticals PLC의 예상 수익은 얼마인가요?
Biodexa Pharmaceuticals PLC은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$3.71
시가
$3.58
일일 범위
$3.51 - $3.72
52주 범위
$2.86 - $96.5
거래량
10.7K
평균 거래량
543.8K
배당수익률
--
EPS(TTM)
-0.01
시가총액
$11.4M
BDRX란 무엇인가요?
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
